Optic Neuritis Treatment Trial Review: 10 year and 15 year (final) results.

Slides:



Advertisements
Similar presentations
The Use of Vitamin D in Clinical Practice
Advertisements

A&P Signs & Symptoms Management of condition
New Multiple Sclerosis Diagnostic Criteria CLINICAL ATTACKS OBJECTIVEADDITIONAL REQUIREMENTS 2 or more None; clinical evidence will suffice 2 or more1Dissemination.
Study Design 121 Relapsing-remitting MS patients randomized to –Stress Management Therapy MS active treatment* 16 individual sessions conducted over 24.
Traumatic Brain Injury Presented by: David L Strauss, Ph.D. ReMed.
Canadian Ophthalmological Society Evidence-based Clinical Practice Guidelines for the Management of Glaucoma in the Adult Eye.
Clinical Guidance and Monitoring for Change Cecilia Fenerty MD FRCOphth.
Devic’s neuromyelitis optica: its distinctive features and treatment
PC Katherine, 28 yo, female Blurred vision R eye HPC Noticed upon awakening 3 days earlier Gradually deteriorated Now has R ocular pain when moved eyes.
Hemi Central Retinal Vein Occlusion
The Optic Neuritis Treatment Trial ( ONTT ) R.R.Battu Narayana Nethralaya Bangalore.
EBM Case discussion 報告者: Intern General datas 26-year old male BW 75kg.
Will my Glaucoma patient lose vision ?
Endometriosis in Caesarean section scar. A Case series. Introduction Scar endometriosis is a relatively rare gynaecological condition that is usually associated.
Neuro week 1 Case 1. Q1 Describe/demonstrate a clinical examination of the eyes that you would perform in your general practice rooms. Katherine, aged.
Sagittal FLAIR images - Stable nonenhancing hyperintensities within the pericallosal white matter and bilateral centrum semiovale, consistent with known.
MS: A Perspective on the African American Experience Mary D. Hughes, MD Medical Director, Neuroscience Associates University Medical Group Greenville Hospital.
TARIQ ALASBALI WHICH PATIENTS ARE AT RISK FOR THE PROGRESSION?
Int J MS Care 7: , 2005/2006. Jan 9 & 10, Clinical Stabilization of a MS Patient after Tonsillectomy presented by Michael C. Levin, MD Department.
Updates on Optic Neuritis Briar Sexton Neuro-ophthalmology Clinical Day Friday, November 18, 2005.
Neuroplasticity and Rehabilitation Strategies Robert K. Shin M.D. VA MS Center of Excellence Assistant Professor Departments of Neurology and Ophthalmology.
We retrospectively analyzed 58 patients with ONSM treated between on a dedicated 6 MV stereotactic LINAC. All cases were discussed in a multidisciplinary.
Canadian Ophthalmological Society Evidence-based Clinical Practice Guidelines for the Management of Glaucoma in the Adult Eye.
TITLE lecturer Institution. Presenter Disclosure Information.
Behcet's Disease in an Indian Patient
Cat Scratch Disease Rupesh Agrawal, Carlos Pavesio
Bartonella Neuroretinitis
Optic neuritis Dr.K.Venkateswarlu M.D;D.M Prof. of Neurology Andhra Medical College.
A CASE OF INFECTIOUS AND AUTOIMMUNE DISEASE COEXISTENCE Elisabetta Miserocchi MD Department of Ophthalmology and Visual Sciences University Hospital San.
Date of download: 5/27/2016 Copyright © 2016 American Medical Association. All rights reserved. From: A Randomized, Placebo-Controlled, Clinical Trial.
Case of the Month – October 2015 Courtesy of IFEC Paris 41 year old Vietnamese male presented to the IFEC Paris outpatient clinic. He played high-level.
Cryptococcus neoformans Choroiditis Rupesh Agrawal, Ho Su Ling, Stephen Teoh Tan Tock Seng Hospital, National Healthcare Group Eye Institute, Singapore.
Summary of “A randomized trial of standard versus intensive blood-pressure control” The SPRINT Research Group, NEJM, DOI: /NEJMoa Downloaded.
Multiple sclerosis – late onset. Authors: Vitalie Vacaras Vitalie Vacaras Damian Popescu Damian Popescu Radu Antonescu Radu Antonescu Anca Simu Anca Simu.
Acute visual loss: Emergency room perspective
Photopsia: Not Just a PVD
OPTIC NEURITIS DR ADNAN.
MS, DNB, FICO, CORNEA & REFRACTIVE SURGERY FELLOWSHIP
Clinical outcomes among patients with chronic low back pain treated with pregabaline monotherapy in fort portal regional referral hospital, “case series”
Figure 1. Onset of PIV catheter complications
Optic Neuritis Uğur Kaan Kalem Dönem V.
1: Houston Methodist Neurological Institute, Houston, TX
Neurologic causes for visual loss in the young adult
Do Alcoholics Respond to Placebo? Results from COMBINE
Junctional scotoma. A 24-year-old woman with multiple sclerosis described a progressive fogginess of vision in her left eye. The visual acuity was 20/20.
Is Non-operative Treatment of Inguinal Hernias a Reasonable Option?
Children’s National Health System ICEOS 2016 – Utrecht, Holland
Copyright © 2006 American Medical Association. All rights reserved.
Multiple Sclerosis.
Neuro-ophthalmology.
From: The Effects of Study Design and Spectrum Bias on the Evaluation of Diagnostic Accuracy of Confocal Scanning Laser Ophthalmoscopy in Glaucoma Invest.
Glaucoma Clinical features and management
PMA Analysis of the CREST Trial Approvability of the RX Acculink Carotid Stent System for Revascularization of Carotid Artery Stenosis in Standard Surgical.
Novel Regimens and Considerations in Radionuclide Therapy for mCRPC
Consultant, Uveitis Service
Anatomical Orientation Clinical Orientation Atlas Fig
2010/10/14 Presented by R4 謝岳哲 Supervisor VS 薛承君 Moderator VS 黃集仁
What Predicts Disability Progression in Multiple Sclerosis?
A b c d Figure 1: Strong T2 weighted images (inversion recovery sequences with fat suppression, TIRM) of a 18 year-old girl document a significant reduction.
Treating to Target in MS
Vogt-Koyanagi Harada Disease
Key Questions for nAMD Treatment Success
Efficacy of transdermal nitroglycerin combined with etodolac for the treatment of chronic post-thoracotomy pain: An open-label prospective clinical trial 
Multiple evanescent white dot syndrome
Figure 3. MRI of compressive optic neuropathy caused by dural lesions in sarcoidosis MRI of compressive optic neuropathy caused by dural lesions in sarcoidosis.
Helen Barraclough, MSc, Ramaswamy Govindan, MD 
Acute Placoid Multifocal Posterior Pigment Epitheliopathy
Using Biomarkers in MS: Initiating With the Right Therapy in Clinical Practice.
Important notes by the doctor
Days without gluten challenge
Presentation transcript:

Optic Neuritis Treatment Trial Review: 10 year and 15 year (final) results

Optic Neuritis – ONTT [10 Years Post] Treatment – IV methylprednisone (1000mg/day x 3 days – Followed by oral prednisone (1mg/kg/day x 14 days) Recovery – Usually recovers VA in about half of the time. Tx v. un-Tx end point is the same. Prognosis – With IV, significantly lower rate of developing MS, and fewer (and less intense) ON attacks. General risk is 38% at 10 year follow-up. Recovery – Strongest indicator of developing MS No MRI lesions: 22% 1 or more lesions: 56%

An Article We Should ALL Read and Be Aware Of… From: Arch Ophthalmol. Vol 121, pp July 2003

!

Gender and Optic Disc Appearance as Predictors of MS

Summary of Results of the ONTT Status Post 10 Years – 10 year (overall) risk of MS was 38% – Patients who had 1 or more typical lesions with MRI had a 56% risk – Those with no lesions had a 22% risk – Lower Risk Factors: No MRI lesions Male No pain ONH swelling

Summary of Results of the ONTT Status Post 15 Years The main conclusions of the 15-year data include: – Visual recovery after optic neuritis was excellent, with > 92% of patients improving to > 20/40 vision. – However, most of these patients still complain that they have reduced visual quality of life; and

Summary of Results of the ONTT Status Post 15 Years Overall, 50% of patients converted to clinically definite MS by 15 years (38% at 10 years). – The risk of developing MS was 25% when baseline MRI was normal – The risk of developing MS was 75% when MRI had 1 or more brain lesions typical for MS. The risk of MS was extremely low in those patients with a normal MRI who were male, with optic nerve swelling or atypical features of optic neuritis.

Summary of Results of the ONTT Status Post 15 Years The main conclusions of the 15-year data include: – Visual recovery after optic neuritis was excellent, with > 92% of patients improving to > 20/40 vision. – However, most of these patients still complain that they have reduced visual quality of life; and

Summary of Results of the ONTT Status Post 15 Years Overall, 50% of patients converted to clinically definite MS by 15 years (38% at 10 years). – The risk of developing MS was 25% when baseline MRI was normal – The risk of developing MS was 75% when MRI had 1 or more brain lesions typical for MS. The risk of MS was extremely low in those patients with a normal MRI who were male, with optic nerve swelling or atypical features of optic neuritis.